Companion Diagnostics Market Growth Projection, COVID-19 Impact Analysis, Sales Statistics, Share Value and Statistics By 2027

Companion Diagnostics Market Analysis

Companion diagnostics (CDx) are diagnostic tests provided in addition to the drug to determine the response in an individual. These can be in-vitro tests or imaging tools and the results are used for furthering the development of the field of theranostics. The global Companion Diagnostics Market report by Market Research Future (MRFR) contains insights and opportunities for the period of 2020 to 2027 (forecast period). It even takes into view, effects and potential impact of COVID-19 on companion diagnostics market.

The Global Companion Diagnostics Market size can reach a valuation of USD 8,081.50 million by 2027. It is predicted to expand at a phenomenal CAGR of 20.29% over the forecast period. Collaboration among co-diagnostic drug companies is one of the major drivers of the market. For instance, F. Hoffman-La Roche and Illumina decided to enter a partnership for increasing patient access to genomic testing. Heightened demand for personalized medicine amid the alarming rise of chronic diseases can drive the demand for CDx tests.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/3077

An increase in clinical trials as well as focus on companion diagnostics in drug development can accelerate the market demand. The use of next-generation sequencing platforms for identifying antibodies which can be harmful as well as selection of vaccine peptides from the sample of COVID-19 to estimate the response rate in clinical trials will bode well for the industry. This can expedite the development of vaccines for the virus. Rapid approvals of drugs by federal regulatory bodies can favor the global Companion Diagnostics Market.

Companion Diagnostics Market Regional Analysis

Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA) are regions taken into consideration with respect to the global Companion Diagnostics Market.

The Americas is touted to lead the companion diagnostics market throughout the forecast period owing to alarming cases of chronic disorders registered and a remarkable healthcare infrastructure to tackle such incidence. According to the National Institutes of Health, close to 1,735,350 cases of cancer were detected in 2018. Efforts by healthcare organizations for creating genomic databases in development of CDx tests will facilitate overall companion diagnostics market growth.

Europe is estimated to assume the second position in the global Companion Diagnostics Market till 2027. Investments in research and development for improving the efficacy of targeted therapy can bode well for the companion diagnostics market. Rise in expendable income levels for affording personalized medicine can be a suitable catalyst for driving the demand for CDx tests.

Companion Diagnostics Market Segmentation

The global companion diagnostics market has been segmented by products & services, technology, indication, and end users.

The market, based on products & services, has been bifurcated into software & services and assays, kits, & reagents.

On the basis of technology, the market has been bifurcated into next-generation sequencing (NGS), polymerase chain reaction (PCR), in-situ hybridization, immunohistochemistry, and others.

The market based on indication has been segmented into cancer, cardiovascular diseases, neurological diseases, infectious diseases, and others. The cancer segment is further sub-segmented into melanoma, breast cancer, lung cancer, colorectal cancer, gastric cancer, and others.

Based on end-user, the companion diagnostics market has been segmented into contract research organizations, pharmaceutical & biopharmaceutical companies, laboratories, and others.

Browse Complete Research Report with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/companion-diagnostic-market-3077

Companion Diagnostics Market Competitive Outlook

Agilent Technologies, Inc., Abnova Corporation, Thermo Fisher Scientific Inc., Guardant Health, bioMérieux SA, Foundation Medicine, Inc., Illumina, Inc., Myriad Genetics, Inc., Invivoscribe, Inc., Abbott, Leica Biosystems Nussloch GmbH, QIAGEN, NG Biotech, ICON plc, F. Hoffmann-La Roche Ltd, and ArcherDX, Inc.  are key players of the global Companion Diagnostics Market. Investments in R&D to improve the current technology for faster identification of symptoms and provide superior products to patients are the key strategy of players to sustain their hold.

Browse More Healthcare Related Research Report at:

antibody drug conjugate market size is likely to grow at a whopping 19% CAGR between 2017- 2023

Spinal Implants Market is expected to accumulate revenues at 5.5% CAGR during the forecast period

Antipsychotic Drugs Market size is expected to reach USD 18.5 billion at a staggering 4.5% CAGR over the forecast period

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: sales@marketresearchfuture.com